GlobeImmune, Inc: GlobeImmune Announces Completion of $7.5 Million Private Placement LOUISVILLE, Colo., Feb. 13, 2014 - GlobeImmune, Inc., today announced that on February 11, 2014, the company completed a $7.5 million private placement of convertible notes and warrants. The notes accrue interest and will be settled in cash or stock under various scenarios. Proceeds from the private placement are to be used for general corporate purposes. SternAegis Ventures, through Aegis Capital Corp., acted as the placement agent for the offering. GlobeImmune is focused on advancing multiple clinical programs in infectious disease and oncology. Ongoing studies of Tarmogen product candidates include a Phase 2 trial of GS-4774 for chronic hepatitis B being conducted by Gilead Sciences, Inc. under the company's license agreement, a Phase 2 trial of GI-6207 in patients with metastatic medullary thyroid cancer being conducted at the National Cancer Institute (NCI), and GI-6301 being developed under a license with Celgene Corporation. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction. About GlobeImmune GlobeImmune is a biopharmaceutical company focused on developing products for the treatment of infectious disease and and oncology based on its proprietary Tarmogen platform. Tarmogens are believed to activate the immune system by stimulating cellular immunity, known as T cell immunity, in contrast to traditional vaccines that predominately stimulate antibody production. To date, Tarmogen product candidates have been generally well tolerated in clinical trials for multiple disease indications and are efficient to manufacture. In May 2009, the company entered into a collaboration agreement with Celgene Corporation focused on the discovery, development and commercialization of product candidates for the treatment of cancer. In October 2011, the company entered into a worldwide, strategic collaboration with Gilead Sciences, Inc., to develop Tarmogens for the treatment of chronic hepatitis B infection. For additional information, please visit the company's website at www.globeimmune.com. ### GlobeImmune Contact: Timothy C. Rodell M.D. President & Chief Executive Officer T: 303-625-2800 email@example.com INVESTOR CONTACT: Susan Noonan S.A. Noonan Communications, LLC T: 212-966-3650 firstname.lastname@example.org Media Contacts: Lena Evans or Tony Russo, Ph.D. Russo Partners, LLC T: 212-845-4262 or 212-845-4251 email@example.com firstname.lastname@example.org ------------------------------------------------------------------------------ This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein. Source: GlobeImmune, Inc via Globenewswire HUG#1761581
GlobeImmune, Inc: GlobeImmune Announces Completion of $7.5 Million Private Placement
Press spacebar to pause and continue. Press esc to stop.